Ann Dermatol.  2010 Aug;22(3):307-311. 10.5021/ad.2010.22.3.307.

Four Cases of Facial Discoid Lupus Erythematosus Successfully Treated with Topical Pimecrolimus or Tacrolimus

Affiliations
  • 1Department of Dermatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. yymmpark6301@hotmail.com
  • 2Department of Rheumatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Abstract

Discoid lupus erythematosus (DLE), which is a cutaneous form of lupus erythematosus (LE), is generally refractory to a wide range of topical or systemic therapies. Although the main treatment option for DLE is topical steroids, it is often ineffective or likely to produce long-term side effects. New drugs, including tacrolimus and pimecrolimus, have been developed to overcome the adverse effects of steroids and treat the lesions of DLE for a prolonged period. We herein report 4 cases of facial DLE successfully treated with therapeutic adjuvants, topical tacrolimus or pimecrolimus.

Keyword

Discoid lupus erythematosus; Pimecrolimus; Tacrolimus

MeSH Terms

Lupus Erythematosus, Discoid
Steroids
Tacrolimus
Steroids
Tacrolimus

Figure

  • Fig. 1 Papulosquamous lesions of patients (cases 1: A, 2: B, 3: C, 4: D) with discoid lupus erythematosus before (a) and after treatment (b).


Cited by  1 articles

Intense Pulsed Light and Q-Switched 1,064-nm Neodymium-Doped Yttrium Aluminum Garnet Laser Treatment for the Scarring Lesion of Discoid Lupus Erythematosus
Yun Sun Byun, Jee Hee Son, Yong Se Cho, Bo Young Chung, Hee Jin Cho, Chun Wook Park, Hye One Kim
Ann Dermatol. 2017;29(3):331-333.    doi: 10.5021/ad.2017.29.3.331.


Reference

1. Rowell NR, Goodfield MJD. Champion RH, Burton JL, Burns DA, Breathnach SM, editors. Systemic lupus erythematosus. Textbook of dermatology. 1998. 6th ed. Oxford: Blackwell Science;2461–2500.
2. Bongu A, Chang E, Ramsey-Goldman R. Can morbidity and mortality of SLE be improved? Best Pract Res Clin Rheumatol. 2002. 16:313–332.
Article
3. Fabbri P, Cardinali C, Giomi B, Caproni M. Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol. 2003. 4:449–465.
4. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999. 141:264–273.
Article
5. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002. 46:495–504.
Article
6. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD, et al. European Tacrolimus Multicenter Atopic Dermatitis Study Group. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med. 1997. 337:816–821.
Article
7. Harper J, Green A, Scott G, Gruendl E, Dorobek B, Cardno M, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol. 2001. 144:781–787.
Article
8. Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium? Arch Dermatol. 1999. 135:574–580.
9. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol. 2002. 47:789–791.
Article
10. Bohm M, Frieling U, Luger TA, Bonsmann G. Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol. 2003. 139:922–924.
Article
11. Kanekura T, Yoshii N, Terasaki K, Miyoshi H, Kanzaki T. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol. 2003. 148:353–356.
Article
12. Druke A, Gambichler T, Altmeyer P, Freitag M, Kreuter A. 0.1% Tacrolimus ointment in a patient with subacute cutaneous lupus erythematosus. J Dermatol Treat. 2004. 15:63–64.
Article
13. Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol. 2002. 12:50–52.
14. Walker SL, Kirby B, Chalmers RJ. The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol. 2002. 147:405–406.
Article
15. de la Rosa Carrillo D, Christensen OB. Treatment of chronic discoid lupus erythematosus with topical tacrolimus. Acta Derm Venereol. 2004. 84:233–234.
Article
16. Heffernan MP, Nelson MM, Smith DI, Chung JH. 0.1% tacrolimus ointment in the treatment of discoid lupus erythematosus. Arch Dermatol. 2005. 141:1170–1171.
Article
17. Kreuter A, Gambichler T, Breuckmann F, Pawlak FM, Stucker M, Bader A, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol. 2004. 51:407–410.
Article
18. Tlacuilo-Parra A, Guevara-Gutierrez E, Gutierrez-Murillo F, Soto-Ortiz A, Barba-Gomez F, Hernandez-Torres M, et al. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford). 2005. 44:1564–1568.
Article
Full Text Links
  • AD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr